Sight Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2022
January 09, 2023 at 09:20 pm
Share
Sight Sciences, Inc. provided revenue guidance for the fourth quarter and year ended December 31, 2022. Fourth quarter 2022 total revenue is expected to be in the range of $20.4 million to $20.6 million, an increase of 40% compared to the prior year period and a sequential increase of 10% compared to the third quarter of 2022 at the estimated midpoint. Surgical Glaucoma revenues are expected to be in the range of $18.7 million to $18.8 million, an increase of 35% compared to the prior year period and a sequential increase of 10% compared to the third quarter at the estimated midpoint. Dry Eye revenues are expected to be in the range of $1.7 million to $1.8 million, an increase of 130% compared to the prior year period and a sequential increase of 9% compared to the third quarter at the estimated midpoint.
Full year 2022 total revenue is expected to be in the range of $71.2 million to $71.4 million, an increase of 46% compared to the prior year at the estimated midpoint. Surgical Glaucoma revenues are expected to be in the range of $65.5 million to $65.6 million, an increase of 41% compared to the prior year at the estimated midpoint. Dry Eye revenues are expected to be in the range of $5.7 million to $5.8 million, an increase of 134% compared to the prior year at the estimated midpoint.
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.